electroCore to Participate at H.C. Wainwright Global Investment Conference
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held on September 9, 2025, at the Lotte New York Palace Hotel in New York.
The company's management team will be available for one-on-one meetings throughout the conference day. Interested investors can schedule meetings through their H.C. Wainwright sales representative or by contacting electroCore's Investor Relations directly.
Details
News Market Reaction – ECOR
On Sep 2, the day this news came out, ECOR closed 0.94% below the previous close.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will take place in New York on Tuesday, September 9, 2025 at the Lotte New York Palace Hotel. Management will host one-on-one meetings throughout the day.
Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at ecor@fnkir.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.